The company is not valued based on ART though. Tha
Post# of 2146
The company is not valued based on ART though. That's the funny part to me. Its trading now on generics only at a low PE of 10. Not even the other R&D products, or products pending approval and launch. Not even on the value of 10% of Novel itself